Asset profile
Blarcamesine
Small molecule
Evidence outlook · program status
Discontinued, as a strategic decision by the sponsor
Market-scoped, absence route. Blarcamesine (ANAVEX2-73) is Anavex Life Sciences' sigma-1 receptor agonist. Its Alzheimer's programme is very much alive (Anavex's 2026-08-25 quarterly update reports submitting all Alzheimer's trial data to a newly opened IND and discussing a Phase 3 protocol with FDA), but that update enumerates the compound's indications as early Alzheimer's disease, Rett syndrome and Fragile X syndrome, states 'These three indications are the Company’s core focus.', and does not mention Parkinson's disease anywhere. The Parkinson's disease dementia programme is therefore recorded as stopped; the release gives no date. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
Also in development:Parkinson's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
119 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 118 same-indication; 24 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Blarcamesine: this drug | Phase 3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | ||
| ANAVEX3-71 | Phase 2 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Entacapone (Comtess) | Approved | Small molecule | COMT | ||
| Foslevodopa / Foscarbidopa (Vyalev) | Approved | Small molecule | dopamine precursor | ||
| Inbrija (CVT-301) | Approved | Small molecule | dopamine precursor | ||
| Istradefylline (Nourianz) | Approved | Small molecule | adenosine A2A | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Levodopa-Carbidopa Intestinal Gel (Duopa) | Approved | Small molecule | dopamine precursor |
…and 104 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.